Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world outcomes of autologous CD19-directed CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A single-center experience

View Full Paper
Ask AI
Bookmark
Share

Authors

PPPhilip PapayanisPVParameswaran VenugopalSNSunita Nathan

Discussion

Loading...

Member takes

Overview

Observational analysis finds 83.3% overall response in large B-cell lymphoma, indicating autologous CAR T-cell therapy's effectiveness.

Key Points

  • Overall response rate was found to be 83.3% with a 60% complete response in treated patients.
  • The median follow-up of 8.6 months revealed no median progression-free survival reached yet.
  • Single-center analysis included patients with relapsed large B-cell lymphoma treated with CAR T-cell therapy.
  • Results highlight the safety and real-world efficacy of autologous CD19-directed CAR T-cell therapy in clinical practice.

Cite This Study

Papayanis et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d42ahttps://doi.org/10.1182/blood-2025-8056
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience2025 · 1 citations
  2. 2Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory B-cell lymphomas: A systematic review and meta-analysis2025
  3. 3Humanized CD19 chimeric antigen receptor (CAR) T-cell therapy for high-risk and post-CAR relapse of B-cell acute lymphoblastic leukemia2025 · 1 citations
  4. 4Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies2025
  5. 5Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma2025 · 5 citations